- Home
- DDI vs ATYR Comparison
DDI vs ATYR Comparison
Compare DDI & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDI
- ATYR
- Stock Information
- Founded
- DDI 2008
- ATYR 2005
- Country
- DDI South Korea
- ATYR United States
- Employees
- DDI N/A
- ATYR N/A
- Industry
- DDI EDP Services
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DDI Technology
- ATYR Health Care
- Exchange
- DDI Nasdaq
- ATYR Nasdaq
- Market Cap
- DDI 472.2M
- ATYR 535.0M
- IPO Year
- DDI 2021
- ATYR 2015
- Fundamental
- Price
- DDI $9.38
- ATYR $1.07
- Analyst Decision
- DDI Strong Buy
- ATYR Buy
- Analyst Count
- DDI 5
- ATYR 5
- Target Price
- DDI $19.60
- ATYR $19.33
- AVG Volume (30 Days)
- DDI 49.7K
- ATYR 12.2M
- Earning Date
- DDI 11-10-2025
- ATYR 11-06-2025
- Dividend Yield
- DDI N/A
- ATYR N/A
- EPS Growth
- DDI N/A
- ATYR N/A
- EPS
- DDI 2.15
- ATYR N/A
- Revenue
- DDI $333,256,000.00
- ATYR N/A
- Revenue This Year
- DDI $16.04
- ATYR $420.85
- Revenue Next Year
- DDI $6.72
- ATYR $1,919.44
- P/E Ratio
- DDI $4.32
- ATYR N/A
- Revenue Growth
- DDI 0.24
- ATYR N/A
- 52 Week Low
- DDI $8.09
- ATYR $1.00
- 52 Week High
- DDI $18.21
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- DDI 45.72
- ATYR 22.27
- Support Level
- DDI $9.20
- ATYR $1.00
- Resistance Level
- DDI $9.74
- ATYR $6.50
- Average True Range (ATR)
- DDI 0.22
- ATYR 0.46
- MACD
- DDI -0.02
- ATYR -0.43
- Stochastic Oscillator
- DDI 19.15
- ATYR 1.18
About DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.